News
CRIS
0.8299
-5.62%
-0.0494
Weekly Report: what happened at CRIS last week (0914-0918)?
Weekly Report · 09/21 09:47
Weekly Report: what happened at CRIS last week (0907-0911)?
Weekly Report · 09/14 09:50
Weekly Report: what happened at CRIS last week (0831-0904)?
Weekly Report · 09/07 09:46
Weekly Report: what happened at CRIS last week (0824-0828)?
Weekly Report · 08/31 09:50
Weekly Report: what happened at CRIS last week (0817-0821)?
Weekly Report · 08/24 09:51
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 08/18 21:06
Analysts Are Bullish on These NA Stocks: Curis (CRIS), Canadian National Railway (CNI)
TipRanks · 08/17 11:40
HC Wainwright & Co. Reiterates Buy on Curis, Maintains $43 Price Target
Benzinga · 08/17 10:14
Weekly Report: what happened at CRIS last week (0810-0814)?
Weekly Report · 08/17 09:51
Curis Inc.’s 1-for-20 Reverse Split Raises Liquidity Concerns and Odd-Lot Trading Risks
TipRanks · 08/16 06:01
Curis prices $5.6 million public offering
Seeking Alpha · 08/13 12:40
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 08/13 12:05
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 08/12 21:06
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 08/11 17:06
Curis files to sell 3.73M shares of common stock, warrants
TipRanks · 08/10 21:35
Weekly Report: what happened at CRIS last week (0803-0807)?
Weekly Report · 08/10 09:48
Weekly Report: what happened at CRIS last week (0727-0731)?
Weekly Report · 08/03 09:48
Curis Regains Nasdaq Compliance, Faces One-Year Monitoring
TipRanks · 07/30 21:20
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Bausch + Lomb Corporation (BLCO) and Curis (CRIS)
TipRanks · 07/29 17:40
Weekly Report: what happened at CRIS last week (0720-0724)?
Weekly Report · 07/27 09:51
More
Webull provides a variety of real-time CRIS stock news. You can receive the latest news about Curis through multiple platforms. This information may help you make smarter investment decisions.
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.